Here are five facts:
1. NVC provided funding for the collaboration to support the development of product candidates for clinical testing.
2. The companies will use Affinivax’s proprietary vaccine platform, Multiple Antigen Presentation System, to develop the vaccines.
3. The CDC predicts that 4 percent of U.S. patients will contract a HAI each year in medical facilities such as ASCs, hospice centers, nursing homes and rehabilitation centers.
4. HAIs cost the United States $9.8 billion annually.
5. The current treatments fighting nosocomial infections have several limitations and there are no vaccines currently available for prevention.
“We are very pleased to have the opportunity to work with NVC to deploy Affinivax’s technology for this important initiative to develop a vaccine to prevent nosocomial infections,” said Steven B. Brugger, CEO of Affinivax.
More articles on quality & infection control:
Changing climate harms growing adolescents — 5 key takeaways
Medication errors witnessed in nearly half of operations in a study: 5 things to know
St. Anthony receives recognition for improvements in patient safety: 3 points
